Please assess the completion status of the following clinical trial:

Trial Title: Platelet Rich Plasma vs Hyaluronic-Acid in Hip OA (Osteoarthritis)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female age 30-72 inclusive.~* Symptomatic early OA of the hip (Kellgren-Lawrence Grade 1-2-3) documented by x-ray taken within the past 6 months.~* Women of childbearing potential will be allowed to enroll but must be willing to practice one highly effective method of contraception (oral, injectable or implanted hormonal methods of contraception, placement of an intrauterine device (IUD) or intrauterine system (IUS) condom or occlusive cap with spermicidal foam/gel/film/cream/suppository, male sterilization, or true abstinence) throughout the study.~Exclusion Criteria:~* Patients with polyarticular disease.~* Patients with major conditions such as poorly control diabetes, Cardiac Heart Failure (CHF), Chronic Obstructive Pulmonary Disease (COPD) or untreated depression~* Patients with known blood disorders (Blood disorders (thrombopathy, thrombocytopenia, anemia with hemoglobin \<9g/dL).~* Patients who had intra-articular treatment with steroids within 6 months of randomization in this study or received more than 3 previous intra-articular steroid injections to the effected hip.~* Patients who are pregnant or nursing at the time of consent.~* Patients with inflammatory arthritic conditions (e.g. rheumatoid arthritis)~* Non-English speaking patients. (Scores used for evaluation have not been validated in Spanish)~* Patients who had previous hip surgery~* Additional disabilities in any of the lower limbs that would interfere with any of the clinical assessments.~* Chronic use of NSAID (defined as taking NSAID regularly every week for the last 6 months), steroids or chemotherapy drugs~* Treatment with NSAIDs within 2 days prior to randomization in this study~* Patients with a BMI over 30. Due to the fact that this study utilize an injection technique which may be inaccurate in obese subjects.

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 72 Years
- Healthy Volunteers: f

Study Arms:
- Autologous PRP Hip Injection (Type: EXPERIMENTAL): Patients randomized to this group of treatment will receive 3 blinded hip intra-articular injections of autologous Platelet-Rich Plasma one week apart from each other.
- Hyaluronic Acid Hip Injection (Type: ACTIVE_COMPARATOR): Patients randomized to this group of treatment will receive 3 blinded hip intra-articular injections of hyaluronic acid (SUPARTZ hyaluronate/2.5ml) one week apart each other.

Based on this trial design, predict the completion outcome and termination type (if applicable).